Literature DB >> 11827732

Chronic inhibition of glutamine synthetase is not associated with impairment of learning and memory in mice.

Marion Blin1, Wim E Crusio, Tobias Hévor, Jean François Cloix.   

Abstract

The convulsant methionine sulfoximine (MSO) is a byproduct of the agenized flour commonly used for feeding domestic animals decades ago. MSO is a powerful glycogenic and epileptogenic agent, and it is an irreversible inhibitor of glutamine synthetase. This latter effect was hypothesized to be responsible for the increase in the incidence of some neuropathologies in humans, such as Alzheimer's disease or Parkinson's disease. In order to test this hypothesis, we chronically administered MSO to two inbred strains of mice, C57BL/6J and BALB/cJ, and analyzed possible alterations in learning and memory features of these mice. Mice were given 20 mg/kg of MSO three times a week for 10 weeks. Spatial learning capabilities assessed with a radial maze were not affected by the long-term MSO treatment, although activity was significantly decreased in BALB/cJ mice. Thus, our data suggest that long-term administration of non-convulsive and non-glycogenic doses of MSO do not alter the spatial memory of mice. Our results do not support the hypothesis that chronic treatment with MSO influences hippocampus-dependent learning abilities in mice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11827732     DOI: 10.1016/s0361-9230(01)00631-1

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  13 in total

1.  In Salmonella enterica, the Gcn5-related acetyltransferase MddA (formerly YncA) acetylates methionine sulfoximine and methionine sulfone, blocking their toxic effects.

Authors:  Kristy L Hentchel; Jorge C Escalante-Semerena
Journal:  J Bacteriol       Date:  2014-11-03       Impact factor: 3.490

2.  Allele-specific conditional destabilization of glutamine repeat mRNAs.

Authors:  Andrew B Crouse; Peter J Detloff
Journal:  Gene Expr       Date:  2005

3.  Effects of glucose and glutamine concentration in the formulation of the artificial cerebrospinal fluid (ACSF).

Authors:  Je Hi An; Yuzhuo Su; Thomas Radman; Marom Bikson
Journal:  Brain Res       Date:  2008-04-15       Impact factor: 3.252

Review 4.  Astrocyte glutamine synthetase: importance in hyperammonemic syndromes and potential target for therapy.

Authors:  Saul W Brusilow; Raymond C Koehler; Richard J Traystman; Arthur J L Cooper
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

5.  Effect of glutamine synthetase inhibition on astrocyte swelling and altered astroglial protein expression during hyperammonemia in rats.

Authors:  H Tanigami; A Rebel; L J Martin; T-Y Chen; S W Brusilow; R J Traystman; R C Koehler
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

Review 6.  Possible treatment of end-stage hyperammonemic encephalopathy by inhibition of glutamine synthetase.

Authors:  Arthur J L Cooper
Journal:  Metab Brain Dis       Date:  2012-10-13       Impact factor: 3.584

7.  Cortical metabolism in pyruvate dehydrogenase deficiency revealed by ex vivo multiplet (13)C NMR of the adult mouse brain.

Authors:  Isaac Marin-Valencia; Levi B Good; Qian Ma; Craig R Malloy; Mulchand S Patel; Juan M Pascual
Journal:  Neurochem Int       Date:  2012-08-03       Impact factor: 3.921

8.  Inhibition of human glutamine synthetase by L-methionine-S,R-sulfoximine-relevance to the treatment of neurological diseases.

Authors:  Thomas M Jeitner; Arthur J L Cooper
Journal:  Metab Brain Dis       Date:  2013-10-18       Impact factor: 3.584

9.  Glutamine is required for persistent epileptiform activity in the disinhibited neocortical brain slice.

Authors:  Hiroaki Tani; Chris G Dulla; John R Huguenard; Richard J Reimer
Journal:  J Neurosci       Date:  2010-01-27       Impact factor: 6.167

Review 10.  Epilepsy, regulation of brain energy metabolism and neurotransmission.

Authors:  Jean-François Cloix; Tobias Hévor
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.